Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of lymphoma called classical Hodgkin Lymphoma (cHL), confirmed by a tissue biopsy, and who have tissue samples or slides available for the study's central review process.
• People aged 65 or older who are not considered suitable for the standard chemotherapy normally used as a first treatment, mainly due to other existing health conditions.
• People who have not yet received any treatment for Hodgkin Lymphoma.
• People whose lymphoma can be detected on a PET scan and has at least one affected lymph node measuring 1.5 cm or more in its longest dimension.
• People whose lymphoma requires full-body (systemic) treatment — meaning all disease stages except a very early, small-burden stage that can be cured with radiation therapy alone.
• People whose general physical health and ability to carry out daily activities falls within an acceptable range for the study (rated 0, 1, or 2 on a standard medical scale).
• People whose blood counts, kidney function, and liver function meet the minimum levels required by the study.
• People with a life expectancy of at least 6 months.
• Men who are sexually active and agree to use effective contraception (such as condoms, vasectomy, or complete abstinence) from the time of signing the consent form until 4 months after the last dose of the study drug.
• People who are willing and able to give written consent to participate, attend all required study visits, and return to the enrolling hospital for follow-up.

Who may not be able to join:

• People diagnosed with a different subtype of Hodgkin Lymphoma called nodular lymphocyte predominant Hodgkin Lymphoma.
• People who have already received any treatment for Hodgkin Lymphoma, including radiation therapy.
• People who have had an active autoimmune disease requiring systemic treatment within the past 2 years (note: people with well-controlled type 1 diabetes, hypothyroidism managed with hormone replacement only, or controlled coeliac disease are not automatically excluded — confirm with trial site).
• People with a known history of serious lung conditions such as interstitial lung disease, lung scarring (pulmonary fibrosis), or non-infectious lung inflammation, or who experience breathlessness at rest or have low oxygen levels while breathing normal air.
• People who have previously been treated with certain types of immunotherapy drugs (anti-PD1, anti-PDL1, anti-PDL2, or anti-CTLA-4 agents) for any condition other than Hodgkin Lymphoma.
• People who have taken high-dose steroid medications or other immune-suppressing drugs within 14 days before registering for the trial (inhaled or topical steroids at low doses may be acceptable — confirm with trial site).
• People with a known HIV infection or infection with human T-cell lymphotropic virus type 1 or 2.
• People with active hepatitis B infection, as determined by specific blood tests (people with past or inactive hepatitis B infection may still be eligible if they are willing to take preventive antiviral medication, and people with hepatitis B immunity from vaccination are not excluded — confirm with trial site).
• People who test positive for hepatitis C antibodies, unless a follow-up test confirms the hepatitis C virus is not currently active in the blood.
• People with a known allergy or sensitivity to the study drug, tislelizumab, or any of its ingredients.
• People with lymphoma that has spread to the brain or the fluid surrounding the brain and spinal cord.
• People with a serious active infection (viral, bacterial, or fungal), including an active COVID-19 infection.
• People with other significant uncontrolled illnesses that, in the treating doctor's judgment, would make participation unsafe or interfere with the study results.
• People who have had major surgery within 4 weeks before the first dose of the study drug.
• People who have received a live vaccine within 4 weeks before the first dose of the study drug.
• People with significant heart or cardiovascular problems, including a heart attack within the past 6 months, unstable chest pain within the past 3 months, severe heart failure, certain serious heart rhythm problems, abnormal heart electrical readings, certain types of heart block without a permanent pacemaker, or uncontrolled high blood pressure.
• People with serious neurological, psychiatric, hormonal, metabolic, immune, or liver conditions that would prevent safe participation or the ability to give informed consent.
• People who have had another active cancer within the past 3 years (some exceptions apply for certain skin cancers or cancers that were fully removed with surgery — confirm with trial site).
• People with a history of severe allergic reactions to other similar antibody-based medications.
• People who are currently participating in another clinical trial involving a treatment.

Important: Always verify eligibility with the trial site directly before applying.